Skip to main content

Advertisement

Log in

Endocrine Therapy in the Preoperative Setting and Strategies to Overcome Resistance

  • Translational Research (Vered Stearns, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Endocrine therapy remains the mainstay for treatment of hormone receptor-positive breast cancer in both adjuvant and metastatic settings. Due to the cytostatic property of endocrine therapy, cytotoxic chemotherapy is more commonly used for cytoreduction in preoperative setting to promote breast-conserving surgery. Nevertheless, recent clinical trials demonstrated that preoperative endocrine therapy can also be used to facilitate breast conservation in patients with locally advanced breast cancer, particularly in postmenopausal women with low proliferative tumors. Multiple markers have been shown to be predictive of endocrine responsiveness, including estrogen and progesterone receptor expression as well as other molecular profiles such as the 21-gene recurrence score assay and PAM-50 assay. The preoperative setting offers a unique situation to rapidly prioritize novel treatment combination and to identify the mechanisms of resistance. Several strategies to overcome resistance, including co-targeting other signaling pathways, particularly human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor (VEGF), and PI3K/Akt/mTOR, are discussed in this review article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bergman L, van Dongen JA, van Ooijen B, van Leeuwen FE. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat. 1995;34(1):77–83.

    Article  PubMed  CAS  Google Scholar 

  2. Hoff PM, Valero V, Buzdar AU, Singletary SE, Theriault RL, Booser D, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer. 2000;88(9):2054–60.

    Article  PubMed  CAS  Google Scholar 

  3. Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78(2):213–7.

    Article  PubMed  CAS  Google Scholar 

  4. Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, De Matteis A, Maiorino L, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14(3):414–20.

    Article  PubMed  CAS  Google Scholar 

  5. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–32.

    Article  PubMed  CAS  Google Scholar 

  6. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.

    Article  PubMed  CAS  Google Scholar 

  7. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.

    Article  PubMed  CAS  Google Scholar 

  8. Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, Bozhok A, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 530 2005.

  9. ••Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9. This is one of the landmark studies that establish the benefit of preoperative endocrine therapy to facilitate BCS. This study also compares the difference between different types of AIs.

    Article  PubMed  CAS  Google Scholar 

  10. Gazet JC, Coombes RC, Ford HT, Griffin M, Corbishley C, Makinde V, et al. Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer. 1996;73(6):758–62.

    Article  PubMed  CAS  Google Scholar 

  11. Kuter I. High-dose neoadjuvant fulvestrant tested January 1, 2008.

  12. Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-Final results at 20-year follow-up. Crit Rev Oncol Hematol. 2010;78(3):260–4.

    Article  PubMed  Google Scholar 

  13. Willsher PC, Robertson JF, Chan SY, Jackson L, Blamey RW. Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer. 1997;33(1):45–9.

    Article  PubMed  CAS  Google Scholar 

  14. Gazet JC, Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988;1(8587):679–81.

    Article  PubMed  CAS  Google Scholar 

  15. Robertson JF, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ. 1988;297(6647):511–4.

    Article  PubMed  CAS  Google Scholar 

  16. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784–96.

    Google Scholar 

  17. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105 Suppl 1:33–43.

    Article  PubMed  CAS  Google Scholar 

  18. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20(3):751–7.

    Article  PubMed  CAS  Google Scholar 

  19. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6.

    Article  PubMed  CAS  Google Scholar 

  20. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 28(30):4594–600.

  21. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.

    Article  PubMed  CAS  Google Scholar 

  22. Alba E, Calvo L, Albanell J, De la Haba J, Chacon J, Arcusa Lanza A, et al. Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: a multicenter, randomized phase II study (GEICAM/2006-03). J Clin Oncol. 2010;28(Suppl) 7s (abstract 500).

  23. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11–24.

    Article  PubMed  CAS  Google Scholar 

  24. •Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95. This mini-review provides concise information about indications of using preoperative endocrine therapy as well as research aspects of this treatment approach.

    Article  PubMed  Google Scholar 

  25. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer. 2010;103(6):759–64.

    Article  PubMed  CAS  Google Scholar 

  26. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26(7):1059–65.

    Article  PubMed  CAS  Google Scholar 

  27. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

    Article  PubMed  CAS  Google Scholar 

  28. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265–77.

    Article  PubMed  CAS  Google Scholar 

  29. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.

    Article  PubMed  Google Scholar 

  30. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167–70.

    Article  PubMed  CAS  Google Scholar 

  31. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.

    Article  PubMed  Google Scholar 

  32. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–8.

    Article  PubMed  CAS  Google Scholar 

  33. ••Brodie A, Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin Cancer Res. 2011. This randomized phase II trial laid the foundation for combining other targeted therapy, particularly drugs that target the PI3K/Akt/mTOR pathway, to prevent and/or reverse endocrine resistance.

  34. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.

    Article  PubMed  CAS  Google Scholar 

  35. Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, et al. TAMRAD: A GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase SABCS, San Antonio; 2010.

  36. Qu Z, Van Ginkel S, Roy AM, Westbrook L, Nasrin M, Maxuitenko Y, et al. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res. 2008;68(15):6232–40.

    Article  PubMed  CAS  Google Scholar 

  37. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res. 2008;6(10):1630–8.

    Article  PubMed  CAS  Google Scholar 

  38. Lee KY, Lee JW, Nam HJ, Shim JH, Song Y, Kang KW. PI3-Kinase/p38 kinase-dependent E2F1 activation is critical for pin1 induction in tamoxifen-resistant breast cancer cells. Mol Cells. 2011.

  39. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010;28(4):628–33.

    Google Scholar 

  40. Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 2008;68(9):3516–22.

    Article  PubMed  CAS  Google Scholar 

  41. Bergh J, Jönsson PE, Lidbrink E, Trudeau M, Eiermann W, Brattström D, et al. First results from FACT—an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer, San Antonio Breast Cancer Symposium; 2009.

  42. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer. 2010;102(6):1010–7.

    Article  PubMed  CAS  Google Scholar 

  43. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.

    Article  PubMed  CAS  Google Scholar 

  44. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res. 2009;69(4):1416–28.

    Article  PubMed  CAS  Google Scholar 

  45. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.

    Article  PubMed  CAS  Google Scholar 

  46. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16(6):1904–14.

    Article  PubMed  CAS  Google Scholar 

  47. Carlson RW, O’Neill A, Vidaurre T, Gomez HL, Badve S. Eastern Cooperative Oncology Group, G. Sledge, Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol. 2009;27:15s, 2009 (suppl; abstr 1013).

    Google Scholar 

  48. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25(25):3816–22.

    Article  PubMed  CAS  Google Scholar 

  49. Chang JCN, Mayer IA, Forero-Torres A, Nanda R, Goetz MP, Rodriguez AA, et al. TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol. 2011; 29(suppl; abstr 505).

  50. Yaich L, Dupont WD, Cavener DR, Parl FF. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 1992;52(1):77–83.

    PubMed  CAS  Google Scholar 

  51. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994;54(10):2552–5.

    PubMed  CAS  Google Scholar 

  52. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res. 1993;53(15):3472–4.

    PubMed  CAS  Google Scholar 

  53. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995;55(11):2279–83.

    PubMed  CAS  Google Scholar 

  54. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000;60(24):6890–4.

    PubMed  CAS  Google Scholar 

  55. • Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole, Cancer Res 2011;71(5):1893–903. Our preclinical study provided a novel treatment option for treating triple-negative breast cancer by using HDAC inhibitor to induce re-expression of ER/PR and render it sensitive to AIs.

    Article  PubMed  CAS  Google Scholar 

  56. Dunbier AK, Ghazoui Z, Anderson H, Smith IE, Dowsett M. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumours identifies determinants of response San Antonio Breast Cancer Symposium; 2010.

  57. Fox EM, Miller TW, Ye F, Shyr Y, Arteaga CL. RNAi screening identifies the insulin/insulin-like growth factor-I receptor pathway as a mechanism of escape from hormone dependence in estrogen receptor-positive breast cancer, San Antonio Breast Cancer Symposium; 2010.

Download references

Disclosure

S. Chumsri has received grant support for clinical trials from Novartis, GlaxoSmithKline, and Merck. A. Brodie has received grants for preclinical studies from Novartis, Syndax, and AstraZeneca

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angela Brodie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chumsri, S., Brodie, A. Endocrine Therapy in the Preoperative Setting and Strategies to Overcome Resistance. Curr Breast Cancer Rep 3, 181–189 (2011). https://doi.org/10.1007/s12609-011-0056-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-011-0056-2

Keywords